Diana Shipping Inc. Announces Time Charter Contract for m/v Los Angeles with MOL and Direct Continuation of Time Charter Contract for m/v DSI Aquarius with Bunge

Diana Shipping Inc. Announces Time Charter Contract for m/v Los Angeles with MOL and Direct Continuation of Time Charter Contract for m/v DSI Aquarius with Bunge GlobeNewswire November 03, 2025 ATHENS, Greece, Nov. 03, 2025 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat […]

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule Company is Well Positioned to Continue to Compete and Grow GlobeNewswire November 03, 2025 MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of

Preshent Advances Its Intelligence Ecosystem Through Multi-Million-Dollar Tribal Initiatives and Global Technology Synergies

Preshent Advances Its Intelligence Ecosystem Through Multi-Million-Dollar Tribal Initiatives and Global Technology Synergies GlobeNewswire November 03, 2025 Milford, CT, Nov. 03, 2025 (GLOBE NEWSWIRE) — Preshent announced new momentum in advancing its intelligent sustainability ecosystem, a unified framework merging artificial intelligence, blockchain, and infrastructure innovation to accelerate the world's transition toward a data-driven transformative economy.

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel GlobeNewswire November 03, 2025 -Publication highlights Deramiocel's anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development- SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics,

Beyond Meat(R) Introduces New Value Pack of Its Latest Beyond Beef(R) at Retailers Across Canada

Beyond Meat(R) Introduces New Value Pack of Its Latest Beyond Beef(R) at Retailers Across Canada The new 2-pack will be rolling into over 1,300 stores across the country GlobeNewswire November 03, 2025 EL SEGUNDO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Beyond Meat, Inc. (NASDAQ: BYND), a leader in plant-based meat, today announced the launch

UTime Limited Explores Application of AI Technology in Health Data Analysis

UTime Limited Explores Application of AI Technology in Health Data Analysis GlobeNewswire November 03, 2025 SHENZHEN, China, Nov. 03, 2025 (GLOBE NEWSWIRE) — UTime Limited (Nasdaq: WTO) today outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies. UTime is developing AI-based algorithm models aimed

Cellectis to Present a Development Update for eti-cel at ASH 2025

Cellectis to Present a Development Update for eti-cel at ASH 2025 GlobeNewswire November 03, 2025 Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHL Preclinical data demonstrated that combining eti-cel with low-dose IL-2 may deepen and extend anti-tumor

Trust Stamp announces a Wallet of Wallets as a component of its new Cryptocurrency and Asset Tokenization Initiative

Trust Stamp announces a Wallet of Wallets as a component of its new Cryptocurrency and Asset Tokenization Initiative Trust Stamp announces a Cryptocurrency Initiative including the TSI Wallet(TM), a biometrically secured digital asset wallet that will both compete with and compliment legacy wallets in the crypto wallet market which is predicted to grow from $14.39B

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting GlobeNewswire November 03, 2025 Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector

VERSES Announces Financing Agreement with a Notional Value of CAD$14 Million and Reduces Staff to Streamline Operations

(Neo:VERS.NE),(OTC US:VRSSF),(Other OTC:VRSSF),(OTC US:VRSSD),(Other OTC:VRSSD),(Neo:VERS), VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company“), a cognitive computing company pioneering next-generation agentic software systems, is pleased to announce that it has arranged a private placement with certain institutional investors (the “Private Placement”). Under the terms

Scroll to Top